Guggenheim Maintains Buy on Immunovant, Raises Price Target to $62
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Guggenheim analyst Yatin Suneja maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $44 to $62.
Guggenheim analyst Yatin Suneja maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $44 to $62.